• Vaccine Name: L. infantum HASPB1 protein vaccine
• Target Pathogen: Leishmania infantum
• Target Disease: Infantile visceral leishmaniasis
• Vaccine Ontology ID: VO_0011351
• Type: Subunit vaccine
• Status: Research
• Antigen: L. infantum HASPB1
• HASPB1 gene engineering:
  • Type: Recombinant protein preparation
  • Description: The L. infantum histone H1 was cloned into the pGEX-KG vector (Amersham Biosciences), expressed in Escherichia coli and purified using GST affinity resin (Amersham Biosciences) (Moreno et al., 2007).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001268
  • Description: Montanide™ ISA 720 (70% formulation, according to manufacturer's instructions, SEPPIC)
• Immunization Route: Intradermal injection (i.d.)

Dog Response

• Host Strain: Beagle
• Vaccination Protocol: Dogs received three intradermal doses (dorsum; 1 ml/dose) of each vaccine formulation for a period of 3 months. On day 0, dogs from group HASPB1 and group H1 received 100 μg of HASPB1 or histone H1 protein. On days 30 and 60 the dogs received 45 μg of either protein. Dogs in group HASPB1 + H1 received a cocktail of histone H1 and HASPB1 (100 μg each) at day 0, and 45 μg of each protein on days 30 and 60. The adjuvant used for dogs in groups HASPB1, H1 and HASPB1 + H1 was Montanide™ ISA 720 (70% formulation, according to manufacturer's instructions, SEPPIC), given on days 0 and 30. The final immunization on day 60 for groups HASPB1, H1, and HASPB1 + H1 was prepared in the absence of adjuvant to avoid side effects observed following the second dose (Moreno et al., 2007).
• Challenge Protocol: Forty-five days following the final immunization, all dogs were infected intravenously with 1 × 10^8 virulent L. infantum promastigotes (Moreno et al., 2007).
• Efficacy: Following infection with L. infantum promastigotes, four out of eight beagle dogs immunized with HASPB1 Montanide remained free of clinical signs, compared to two out of eight dogs in the control group. The results demonstrate that HASPB1 antigens with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions (Moreno et al., 2007).